What is eGenesis?
Founded in 2015 and headquartered in Cambridge, Massachusetts, eGenesis is at the forefront of gene editing and genome engineering. The company is dedicated to developing solutions for the critical shortage of transplantable organs, tissues, and cells. By leveraging advanced genetic technologies, eGenesis aims to create a sustainable and scalable source of biological materials for transplantation, potentially revolutionizing patient care and outcomes for those suffering from organ failure. Their work is positioned to address a significant global health challenge.
How much funding has eGenesis raised?
eGenesis has raised a total of $456M across 5 funding rounds:
Angel/Seed
$2M
Series A
$38M
Series B
$100M
Series C
$125M
Series D
$191M
Angel/Seed (2016): $2M, investors not publicly disclosed
Series A (2017): $38M led by Alexandria Equities, Heritage Provider Network, Alta Partners, ARCH Venture Partners, Khosla Ventures Acquisition, and Biomatics Capital
Series B (2019): $100M supported by Khosla Ventures Acquisition, Wellington Partners, Biomatics Capital, Leaps by Bayer, Alta Partners, Fresenius Medical Care Ventures, and Arch Venture Partners
Series C (2021): $125M featuring Polaris Partners Pte. Ltd, Farallon Capital Management , L.L.C., The Invus Group , LLC, Samsara BioCapital, and HBM Healthcare Investments AG
Series D (2024): $191M backed by Khosla Ventures, Lux Capital, and Arch Capital
Key Investors in eGenesis
Khosla Ventures
Khosla Ventures is a venture capital firm that provides venture assistance and strategic advice to entrepreneurs working on breakthrough technologies across various sectors including health and AI.
Lux Capital
Lux Capital is a venture capital firm investing in early-stage and growth-stage companies at the intersection of science and technology, including biotechnology.
Arch Capital
Arch Capital Group Ltd. is a global financial services company that writes insurance, reinsurance, and mortgage insurance, with a significant presence in the life sciences sector through its investment activities.
What's next for eGenesis?
The substantial enterprise-level funding and recent strategic investment signal a new phase of accelerated growth and development for eGenesis. This capital infusion is expected to fuel further research and development, scale up manufacturing capabilities, and potentially advance clinical trials. The company's focus on gene editing for organ transplantation places it in a high-growth, high-impact sector of biotechnology. Future strategic partnerships and continued innovation will be key as eGenesis works towards bringing its groundbreaking therapies to market and addressing the global organ shortage.
See full eGenesis company page
